Sara Belko

Ms. Sara Belko

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Journal of Vascular Surgery Cases, Innovations and Techniques
Verified
Journal Article
Open access
MRMartina Rama
Martina Rama
WNWissam Nasser
Wissam Nasser
PPPrashanth Palvannan
Prashanth Palvannan
SBSara Belko
Sara Belko
PDPaul DiMuzio
Paul DiMuzio
FPFrancesco Palazzo
Francesco Palazzo
Median arcuate ligament (MAL) syndrome (MALS) is a rare condition caused by compression of the celiac artery by the MAL. Symptoms include abdominal pain, nausea, and weight loss. Rarely, the MAL can compress both the celiac artery and the superior mesenteric artery (SMA). We describe the case of a young man with MALS involving the celiac artery and SMA. Laparoscopic release of the MAL was performed, and the patient had resolution of his symptoms at 6 months of follow-up. A review of the literature identified only six cases of MALS involving the SMA and celiac artery, making this a rare occurrence.

12 November 2023 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
SBSara Belko
Sara Belko
MHMorgan Hutchinson
Morgan Hutchinson
GHGeoffrey Hayden
Geoffrey Hayden
RPRobert Pugliese
Robert Pugliese
More than 537 million adults worldwide are living with diabetes and navigating its health and lifestyle impact. People living with diabetes face unique challenges in managing their diet and exercise, monitoring their blood glucose, self-administering medications, and effectively integrating their disease into their social activities. In addition to diabetes being a challenging multifactorial disease, these challenges arise in part from patients having to navigate a complex ecosystem where sectors are siloed and its services, products, and environments are not designed with the patient in mind. To address these challenges, the ecosystem of diabetes care, including researchers, healthcare professionals, product and service developers, and policymakers, can adopt co-design methodologies providing patients and caregivers a seat at the table when creating solutions. Co-design in healthcare is an approach to problem-solving where patients are viewed as equal partners providing their own unique perspective and expertise, to design and develop devices, services, and environments. Co-design emphasizes the value of the user’s insights and expertise. Incorporating patient perspective has been shown to increase patient empowerment and satisfaction, enhance healthcare technology value, and strengthen the collaboration between the patient and their interprofessional ecosystem. We describe opportunity spaces, successful examples, and strategies to better engage patients in research, policymaking, and healthcare product, service, and environment development through co-design methods. By incorporating co-design, the ecosystem of diabetes care can deliver more effective, high-quality patient-centered care, products, and services.

13 November 2024 in Brachytherapy
Verified
Journal Article
Closed access
Firas MourtadaFiras Mourtada
Firas Mourtada
SBSara Belko
Sara Belko
RMRachel Monane
Rachel Monane
RPRobert Salvatore Pugliese
Robert Salvatore Pugliese
LKLydia Komarnicky-Kocher
Lydia Komarnicky-Kocher
JEJacqueline Emrich
Jacqueline Emrich

5 February 2025 in JMIR Serious Games
Verified
Journal Article
Open access
RWRichard Wu
Richard Wu
KCKeerthana Chakka
Keerthana Chakka
SBSara Belko
Sara Belko
NKNinad Khargonkar
Ninad Khargonkar
KDKevin Desai
Kevin Desai
TAThiru Annaswamy
Thiru Annaswamy
Background: Current telemedicine technologies are not fully optimized for conducting physical examinations. The Virtual Remote Tele-Physical Examination (VIRTEPEX) system, a novel proprietary technology platform using a Microsoft Kinect-based augmented reality game system to track motion and estimate force, has the potential to assist with conducting asynchronous, remote musculoskeletal examinations. Objective: This pilot study evaluated the feasibility of the VIRTEPEX system as a supplement to telehealth musculoskeletal strength assessments. Methods: In this cross-sectional pilot study, 12 study participants with upper extremity pain and/or weakness underwent strength evaluations for four upper extremity movements using in-person, telehealth, VIRTEPEX, and composite (telehealth plus VIRTEPEX) assessments. The evaluators were blinded to each other’s assessments. The primary outcome was feasibility, as determined by participant recruitment, study completion, and safety. The secondary outcome was preliminary evaluation of inter-rater agreement between in-person, telehealth, and VIRTEPEX strength assessments, including κ statistics. Results: This pilot study had an 80% recruitment rate, a 100% completion rate, and reported no adverse events. In-person and telehealth evaluations achieved highest overall agreement (85.71%), followed by agreements between in-person and composite (75%), in-person and VIRTEPEX (62.5%), and telehealth and VIRTEPEX (62.5%) evaluations. However, for shoulder flexion, agreement between in-person and VIRTEPEX evaluations (78.57%; κ=0.571, 95% CI 0.183 to 0.960) and in-person and composite evaluations (78.57%; κ=0.571, 95% CI 0.183 to 0.960) was higher than that between in-person and telehealth evaluations (71.43%; κ=0.429, 95% CI −0.025 to 0.882). Conclusions: This study demonstrates the feasibility of asynchronous VIRTEPEX examinations and supports the potential for VIRTEPEX to supplement and add value to standard telehealth platforms. Further studies with an additional development of VIRTEPEX and larger sample sizes for adequate power are warranted.

8 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LWLydia J Wilson
Lydia J Wilson
SBSara Belko
Sara Belko
EGEric Gingold
Eric Gingold
SWShuying Wan
Shuying Wan
RMRachel Monane
Rachel Monane
Firas MourtadaFiras Mourtada
Firas Mourtada
Background/Objectives: Accurate patient-specific dosimetry is essential for optimizing radiopharmaceutical therapy (RPT), but current tools lack validation in clinically realistic conditions. This work aimed to develop a workflow for designing and fabricating patient-derived, organ-realistic RPT phantoms and evaluate their feasibility for commissioning patient-specific RPT radioactivity quantification. Methods: We used computed tomographic (CT) and magnetic resonance (MR) imaging of representative patients, computer-aided design, and in-house 3D printing technology to design and fabricate anthropomorphic kidney and parotid phantoms with realistic organ spacing, anatomically correct orientation, and surrounding tissue heterogeneities. We evaluated the fabrication process via geometric verification (i.e., volume comparisons) and leak testing (i.e., dye penetration tests). Clinical feasibility testing involved injecting known radioactivities of 177Lu-PSMA-617 into the parotid and kidney cortex phantom chambers and acquiring SPECT/CT images. MIM SurePlan MRT SPECTRA Quant software (v7.1.2) reconstructed the acquired SPECT projections into a quantitative SPECT image and we evaluated the accuracy by region-based comparison to the known injected radioactivities and determined recovery coefficients for each organ phantom. Results: Phantom fabrication costs totaled < USD 250 and required <84 h. Geometric verification showed a slight systematic expansion (<10%) from the representative patient anatomy and leak testing confirmed watertightness of fillable chambers. Quantitative SPECT imaging systematically underestimated the injected radioactivity (mean error: −17.0 MBq; −13.2%) with recovery coefficients ranging from 0.82 to 0.93 that were negatively correlated with the surface-area-to-volume ratio. Conclusions: Patient-derived, 3D-printed fillable phantoms are a feasible, cost-effective tool to support commissioning and quality assurance for patient-specific RPT dosimetry. The results of this work will support other centers and clinics implementing patient-specific RPT dosimetry by providing the tools needed to comprehensively evaluate accuracy in clinically relevant geometries. Looking forward, widespread accurate patient-specific RPT dosimetry will improve our understanding of RPT dose response and enable personalized RPT dosing to optimize patient outcomes.

17 February 2024 in JMIR Preprints
Verified
Preprint
Open access
RWRichard Wu
Richard Wu
KCKeerthana Chakka
Keerthana Chakka
SBSara Belko
Sara Belko
NKNinad Khargonkar
Ninad Khargonkar
KDKevin Desai
Kevin Desai
TAThiru Annaswamy
Thiru Annaswamy
BACKGROUND Current telemedicine technology is not optimized for conducting physical examinations. The Virtual Remote Tele-Physical Examination (VIRTEPEX) system, a novel proprietary technology platform which uses a Microsoft Kinect-based augmented reality game system to track motion and estimate force, has potential to assist with conducting asynchronous, remote musculoskeletal examination. OBJECTIVE This pilot study evaluates the feasibility of the VIRTEPEX system for supplementing telehealth musculoskeletal strength assessments. METHODS In this cross-sectional pilot study, 12 study participants with upper extremity pain and/or weakness underwent in-person, telehealth, VIRTEPEX, and composite (telehealth plus VIRTEPEX) strength evaluations for four upper extremity movements. Evaluators were blinded to one another’s evaluations. The primary outcome was feasibility, as determined by participant study recruitment, completion, and safety. The secondary outcome was preliminary assessment of inter-rater agreements between in-person, telehealth, and VIRTEPEX strength assessments, plus kappa statistical calculations. RESULTS This pilot study had an 80% recruitment rate, 100% completion rate, and 0 adverse events. In-person and telehealth evaluations had highest overall agreement (85.71%), greater than the agreements between in-person and VIRTEPEX (62.50%), in-person and composite (75%), and telehealth and VIRTEPEX evaluations (62.50%). However, for shoulder flexion, agreement between in-person and VIRTEPEX (78.57%, κ=0.571, 95% CI of 0.183 to 0.960), and also in-person and composite evaluations (78.57%, κ=0.571, 95% CI of 0.183 to 0.960), was greater than that for in-person and telehealth (71.43%, κ=0.429, 95% CI of -0.025 to 0.882). CONCLUSIONS This work demonstrates the feasibility of asynchronous VIRTEPEX examination and supports the potential for VIRTEPEX to supplement and add value to standard telehealth platforms. Further study, with additional development of VIRTEPEX and larger sample size for adequate power, is warranted.